顺铂与唑来膦酸序贯应用抑制肺癌细胞增殖的研究

doi:10.12092/j.issn.1009-2501.2018.09.010

中国临床药理学与治疗学 ›› 2018, Vol. 23 ›› Issue (9): 1027-1030.doi: 10.12092/j.issn.1009-2501.2018.09.010

顺铂与唑来膦酸序贯应用抑制肺癌细胞增殖的研究

秦博宇，王刚，齐晓光，王雅捷，孙琼，孙胜杰

中国人民解放军总医院肿瘤内科，北京 100853，北京

收稿日期:2018-02-05 修回日期:2018-05-06 出版日期:2018-09-26 发布日期:2018-09-26
通讯作者: 孙胜杰，男，博士，副主任医师，主要从事肺癌靶向及免疫治疗的临床及基础研究。 Tel:010-66937878 E-mail:sunsj301@sina.com
作者简介:秦博宇，女，硕士，医师，主要从事恶性肿瘤精准治疗的临床及基础研究。 Tel:010-66937878 E-mail:qpm2017@126.com
基金资助:
解放军总医院临床科研扶持基金（2015FC-ZHCG-2001, 2017FC-ZHCG-3001）

Inhibitory effect of cisplatin combined with zoledronic acid on the cell proliferation of lung cancer

QIN Boyu, WANG Gang, QI Xiaoguang, WANG Yajie, SUN Qiong, SUN Shengjie

Department of Oncology, Chinese PLA General Hospital, Beijing 100853, China

Received:2018-02-05 Revised:2018-05-06 Online:2018-09-26 Published:2018-09-26

摘要/Abstract

摘要：

目的: 探讨顺铂与唑来膦酸序贯联合应用对人肺巨细胞癌细胞株PLA-801D的生长抑制作用。方法: MTT法测定顺铂与唑来膦酸不同序贯方式处理后细胞生长的抑制率，并通过流式细胞术分析不同处理组细胞周期的变化。结果: 顺铂和唑来膦酸均能够抑制肿瘤细胞的生长，并在一定给药浓度范围内具有剂量依赖效应。两药联合应用对细胞生长抑制具有协同效应，其中以顺铂给药24 h后序以唑来膦酸处理对细胞生长的抑制效果最佳。顺铂与唑来膦酸序贯方式的改变，引起G0/G1期细胞比例下降，S期细胞比例显著提高。结论: 先顺铂后唑来膦酸的联合给药方式对肺癌细胞的生长抑制作用最强，不同序贯应用方式导致细胞生长抑制率的差异与细胞周期的变化具有一定的相关性。

关键词: 顺铂, 唑来膦酸, 肺癌, 生长抑制率, 细胞周期

Abstract:

AIM: To investigate the inhibitory effect of cisplatin combined with zoledronic acid on lung cancer cell PLA-801D proliferation. METHODS: Cell growth inhibitory rate of cisplatin combined with zoledronic acid was determined with MTT assay. The cell cycle was detected by flow cytometry. RESULTS: Cell proliferation was inhibited under the treatment of cisplatin, zoledronic acid alone. The inhibitory rate showed a dose dependent effect within a certain drug concentration range. Compared with single-drug treatment, the combined treatment of cisplatin and zoledronic acid showed a synergistic effect on cell growth inhibition. The highest inhibitory rate was found in sequential cisplatin+zoledronic acid group (cells were first incubated with cisplatin followed by zoledronic acid treatment 24 h later). In addition, compared with the control group, the S phase was longer after combined treatment of cisplatin and zoledronic acid. CONCLUSION: Sequential treatment of cisplatin and zoledronic acid show the strongest inhibitory effect on the cell proliferation of lung cancer. The ranged inhibitory effect may be related with the change of cell cycle.

Key words: cisplatin, zoledronic acid, lung cancer, cell growth inhibitory rate, cell cycle

中图分类号:

R965.2

秦博宇，王刚，齐晓光，王雅捷，孙琼，孙胜杰 . 顺铂与唑来膦酸序贯应用抑制肺癌细胞增殖的研究[J]. 中国临床药理学与治疗学, 2018, 23(9): 1027-1030.

QIN Boyu, WANG Gang, QI Xiaoguang, WANG Yajie, SUN Qiong, SUN Shengjie. Inhibitory effect of cisplatin combined with zoledronic acid on the cell proliferation of lung cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(9): 1027-1030.

参考文献

［1］孙燕,管忠震,廖美琳，等.肺癌骨转移诊疗专家共识(2014版)［J］.中国肺癌杂志,2014,95(2):57-72.
［2］Tsuya A, Kurata T, Tamura K, et al. Skeletal metastases in non-small cell lung cancer: a retrospective study［J］. Lung Cancer, 2007, 57(2): 229-232.
［3］Mundy GR.Metastasis to bone: causes, consequences and therapeutic opportunities［J］.Nat Rev Cancer, 2002, 2(8): 584-593.
［4］Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs［J］. J Clin Oncol, 2003, 21(7): 1404-1411.
［5］Williams G, Pazdur R, Temple R.Assessing tumor-related signs and symptoms to support cancer drug approval［J］. J Biopharm Stat, 2004, 14(1): 5-21.
［6］Isla D,Afonso R,Bosch-Barrera J,et al.Zoledronic acid in lung cancer with bone metastases:a review［J］.Expert Rev Anticancer Ther,2013,13(4):421-426.
［7］Neville-Webbe HL, Coleman RE, Holen I. Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction［J］. Br J Cancer, 2010, 102(6): 1010-1017.
［8］茆勇, 马凤锦, 黄朝晖，等.顺铂联合唑来膦酸对肺癌A549细胞增殖的影响及其机制［J］.中华实验外科杂志, 2011, 28(11): 1939-1940.
［9］Ibrahim T, Liverani C, Mercatali L, et al.Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines［J］. Int J Oncol, 2013, 42(4): 1263-1270.
［10］You Y, Li H, Chen J, et al.Zoledronic acid reverses cisplatin resistance in nasopharyngeal carcinoma cells by activating the mitochondrial apoptotic pathway［J］. Oncol Lett, 2017, 13(3): 1840-1846.
［11］Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial［J］. Cancer, 2004, 100(12): 2613-2621.
［12］Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair［J］. J Biol Chem, 1994, 269(2): 787-790.
［13］王增, 卢红阳, 翁琳.唑来瞵酸抗肿瘤作用的临床研究进展［J］.中国临床药理学与治疗学, 2011, 16(8): 945-950.
［14］陈芳君，王增，蔡鑫君，等. 靶向肿瘤新生血管唑来膦酸阳离子隐形脂质体抗肿瘤作用的研究［J］. 中国临床药理学与治疗学, 2017, 22(1): 33-36.
［15］Guenther A, Gordon S, Tiemann M, et al.The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation［J］. Int J Cancer, 2010, 126(1): 239-246.
［16］Almubarak H, Jones A, Chaisuparat R, et al. Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers［J］. J Carcinog, 2011, 10(1): 2.
［17］ Iguchi T, Miyakawa Y, Saito K, et al.Zoledronate-induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM/Chk1/cdc25 pathway in human osteosarcoma cells［J］. Int J Oncol, 2007, 31(2): 285-291.
［18］Ohnuki H, Izumi K, Terada M, et al.Zoledronic acid induces S-phase arrest via a DNA damage response in normal human oral keratinocytes［J］. Arch Oral Biol, 2012, 57(7): 906-917.
［19］Ozturk OH, Bozcuk H, Burgucu D, et al. Cisplatin cytotoxicity is enhanced with zoledronic acid in A549 lung cancer cell line: preliminary results of an in vitro study［J］.Cell Biol Int, 2007, 31(9): 1069-1071.

[1]	游蓉丽, 黄玉荣, 毛睿, 海丽娜, 王颖莉, 王艳. 基于血清代谢组学与网络药理学探究复方苦参注射液治疗肺癌的作用机制[J]. 中国临床药理学与治疗学, 2023, 28(9): 988-999.
[2]	付婷, 李芳, 潘大燕, 夏园园, 张秋园. 肺癌细胞外泌体来源的miR-718通过靶向PTEN诱导血管新生的研究[J]. 中国临床药理学与治疗学, 2023, 28(6): 624-632.
[3]	李菲, 丁慧琴, 陈梦静. 异莲心碱激活ERK信号通路诱导肺癌PC9细胞自噬的作用研究[J]. 中国临床药理学与治疗学, 2023, 28(11): 1235-1240.
[4]	刘佳君, 阙祖俊, 田建辉. 金复康有效成分抑制肺癌循环肿瘤细胞募集中性粒细胞能力的比较研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 1-9.
[5]	苏洋, 周峰, 丁金磊. 艾司氯胺酮复合舒芬太尼对胸腔镜肺癌根治术后情绪及镇痛的影响[J]. 中国临床药理学与治疗学, 2023, 28(1): 59-65.
[6]	黄小明, 杜野, 林少明, 沈观乐. 呼吸道微生态对晚期非小细胞肺癌患者接受PD-1抑制剂单药治疗疗效影响的探索性研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 66-74.
[7]	周欢, 徐铭, 李波, 刘春英, 王淳. PI3K/Akt/FOXO3a信号通路介导的保护性自噬参与肺腺癌获得性顺铂耐药表型重塑[J]. 中国临床药理学与治疗学, 2022, 27(9): 961-970.
[8]	张可心, 贾文静, 崔佳文, 敖路遥, 周芳, 王广基, 刘嘉莉. 第三代EGFR酪氨酸激酶抑制剂在非小细胞肺癌临床治疗中的应用及研究进展[J]. 中国临床药理学与治疗学, 2022, 27(9): 1016-1030.
[9]	王琳, 李重阳, 李帅虎, 高盛涵, 徐甜, 李飞. 肺癌中致病融合基因的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(8): 877-885.
[10]	王新丽, 许霞青, 方寒冰, 郭玉忠. 佛波酯增强顺铂的抗肿瘤活性及降低其肾毒性的作用研究[J]. 中国临床药理学与治疗学, 2022, 27(5): 535-543.
[11]	赵子文, 范方田, 蒋志君. 诱导性支气管相关淋巴组织（iBALT）形成与相关肺疾病的研究[J]. 中国临床药理学与治疗学, 2022, 27(3): 353-360.
[12]	叶凯丽, 郑雯, 叶啟发, 杨岚. CDK1参与肝细胞癌的发展机制及其抑制剂应用价值[J]. 中国临床药理学与治疗学, 2021, 26(9): 1086-1094.
[13]	崔华, 燕红霞, 尹梅. 下调lncRNA LINC00176对肺癌A549/DDP细胞顺铂耐药和自噬的影响[J]. 中国临床药理学与治疗学, 2021, 26(6): 616-623.
[14]	刘云帆, 杜月梅, 刘晓艺, 高丽萍. 枸杞多糖对顺铂诱导小鼠睾丸支持细胞凋亡的影响[J]. 中国临床药理学与治疗学, 2021, 26(6): 624-630.
[15]	黄伊婷, 沈爱宗. 阿法替尼治疗肺癌的临床疗效与安全性[J]. 中国临床药理学与治疗学, 2021, 26(4): 474-480.

顺铂与唑来膦酸序贯应用抑制肺癌细胞增殖的研究

Inhibitory effect of cisplatin combined with zoledronic acid on the cell proliferation of lung cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价